[CAS NO. 33069-62-4]  Paclitaxel

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [33069-62-4]

Store
Catalog
HY-B0015
Brand
MCE
CAS
33069-62-4

DESCRIPTION [33069-62-4]

Overview

MDL-
Molecular Weight853.91
Molecular FormulaC47H51NO14
SMILESO=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O

For research use only. We do not sell to patients.

129 Publications Citing Use of MCE


Summary

Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy [1] [2] .


IC50 & Target

Traditional Cytotoxic Agents


In Vitro

Paclitaxel (20 nM; 48 hours) induces programmed cell death and exists a block at the G2/M phase of the cell cycle [1] .
Paclitaxel (20 nM; 48 hours) induces a consistent increase in the level of p53 [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis [1]

Cell Line: MCF-7, MDA-MB-231 cells
Concentration: 20 nM
Incubation Time: 48 hours
Result: Induced programmed cell death.

Cell Cycle Analysis [1]

Cell Line: MCF-7, MDA-MB-231 cells
Concentration: 20 nM
Incubation Time: 48 hours
Result: >60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament.

Western Blot Analysis [1]

Cell Line: MCF-7 cells (harboring wild-type p53)
Concentration: 20 nM
Incubation Time: 48 hours
Result: Induced a consistent increase in the level of p53.

In Vivo

Paclitaxel (1-20 mg/kg; i.p.; 1 time/2 days for five cycles) obviously induces liver metastases at the low-Paclitaxel group with little influence on primary tumor growth [3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MDA-231 xenograft-bearing mice [3]
Dosage: 1, 20 mg/kg
Administration: Intraperitoneal injection; five cycles (1 time/2 days)
Result: Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT00730353 Hoosier Cancer Research Network|Pfizer
Esophageal Cancer
August 2008 Phase 2
NCT03377491 NovoCure Ltd.
Pancreas Adenocarcinoma
May 10, 2018 Phase 3
NCT02041338 Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer|Neoadjuvant Chemotherapy
January 2014 Phase 2

Appearance

Solid



Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)


Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 117.11 mM ; Need ultrasonic)

H 2 O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1711 mL 5.8554 mL 11.7108 mL
5 mM 0.2342 mL 1.1711 mL 2.3422 mL
10 mM 0.1171 mL 0.5855 mL 1.1711 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: corn oil

    Solubility: 10 mg/mL (11.71 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (2.44 mM); Suspended solution; Need ultrasonic

  • 4.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αRS)-
Tax-11-en-9-one, 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
Taxol
NSC 125973
Taxol A
Paclitaxel
BMS 181339-01
Yewtaxan
Plaxicel
ABI 007
TaxAlbin
QW 8184
Ebetaxel
Capxol
MBT 0206
Abraxane
Genexol-PM
Pacliex
Genexol
Genetaxyl
NK 105
Mitotax
OncoGel
Onxal
DHP 107
EndoTAG 1
Genaxol
Intaxel
Taxus
TAXUS stent
(-)-Paclitaxel
Taxus Liberte
EmPAC
Tocosol Paclitaxel
Cyclopax
Zisu
LEP-ETU
Liposome-entrapped paclitaxel easy-to-use
Paxene
Infinnium
Padexol
Sindaxel
Nanoxel
5β,20-Epoxy-1,2a,4,7β,10β,13α-hexahydroxy-tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
PTX
Cypher select
Coroflex Please
Nab-paclitaxel
TAXUS Express
IG 001
Cynviloq
IG 002
Nanotax
Pacitaxel
Cremophor-free paclitaxel
Oraxol
Anzatax
Pazenir
Apealea